| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Ophthalmologic System | ||
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Ophthalmologic System | ||
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Ophthalmologic System |
Recent Updates
Recently added Catalysts
Aura Biosciences, Inc.$6.84
-0.16 (-2.29%)
D 25Pipeline Score Richly Valued Biotech · Clinical
Market Cap
713.37 M
EPS
-1.76
P/E Ratio
-3.91 $
Value Trade
1.73 M
SEC Financials
Q1 2026Dilution Risk
40%R&D Expenses
27.96 M
Operating CF
-29.89 M
Total Assets
137.68 M
Total Liabilities
30.43 M
Equity
107.25 M
D/E Ratio
12,345
-3.18 %
Week
1.74 %
1 Month
40.22 %
3 Month
42.32 %
6 Month
-46.1 %
5 Year
-46.1 %
All Time
Cash Data
Cash Position
114.73 M
Monthly Burn
9.96 M
Runway
9.7 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
442.81 K
52 Week Range
4.73 - 9.54
% held by Insiders
37.58 %
% held by Institutions
34.23 %
Enterprise Value
615.63 M
Total Shares
64.21 M
Short %
15.67 %
Float Shares
44.24 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Aura Biosciences, Inc.
200Total events
2Upcoming
28Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 2
Event history 198
Jul 8, 2026
▲Enrollment CompleteBel-sarTrial
Enrollment completed in Phase 3 CoMpass trial
early choroidal melanomasource ↗
Jun 1, 2026
▲Enrollment CompleteBel-sarTrial
Enrollment completed in Phase 3 CoMpass trial of bel-sar in early choroidal melanoma
early choroidal melanomasource ↗
Jun 2026
◆Topline ReadoutBel-sarClinical Data
Initial three-month clinical data expected mid-2026
non-muscle invasive bladder cancer (NMIBC)source ↗
May 27, 2026
◆Oral PresentationPresentation
TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
May 19, 2026
May 5, 2026
▼Equity OfferingCorporate
Closing of $299 million public offering including full exercise of underwriters' option
May 4, 2026
▼Equity OfferingCorporate
Pricing of $260 million public offering of common stock and pre-funded warrants
May 4, 2026
◆Enrollment UpdateBel-sarTrial
86 patients enrolled; over 25 additional patients scheduled or identified for screening through May 2026
early choroidal melanomasource ↗
Drug Pipeline Intelligence
D25
Pipeline Score $7M
Pipeline ValueRichly Valued
Valuation Signal3
Drugs Scored0.0x
rNPV / MCap Top 26%
Micro Cap (rank 675 of 911)
Percentile RankAura Biosciences, Inc. faces pipeline headwinds (25/100), with $32M risk-adjusted pipeline value, led by AU-011 in Uveal Melanoma (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AU-011 Small molecule | Uveal Melanoma | Phase 2 | NCT04417530 | 10% | $24M | COMPLETED | 22 | - | - | Apr 22, 2024 | - | Mar 3, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
— | ocular and urologic cancers | Phase 2 | 2025-05-16 | positive data from Phase 2 trials, showing efficacy in targeting tumors and preserving organ function Read More | May 2025 Innovating the future of cancer care to cure patients and preserve organ function Legal disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this caut Read More | |
— | ocular and urologic cancers | Phase 2 | 2025-05-16 | positive data from Phase 2 trials, showing efficacy in targeting tumors and preserving organ function Read More | May 2025 Innovating the future of cancer care to cure patients and preserve organ function Legal disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this caut Read More | |
— | ocular and urologic cancers | Phase 2 | 2025-05-16 | positive data from Phase 2 trials, showing efficacy in targeting tumors and preserving organ function Read More | May 2025 Innovating the future of cancer care to cure patients and preserve organ function Legal disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this caut Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AURA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AURA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AURA▼ -2.3%today
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
Aura Biosciences has appointed Jeremy Bender, Ph.D., M.B.A., to its Board of Directors. Bender brings extensive experience in biotechnology and oncology, which is expected to enhance Aura's strategic direction as it approaches regulatory approval for its lead candidate, bel-sar. The company is also completing its Phase 3 CoMpass trial for early choroidal melanoma.
Read more →AURAAura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
Aura Biosciences has completed patient enrollment in its Phase 3 CoMpass trial for belzupacap sarotalocan (bel-sar) aimed at treating early choroidal melanoma. A total of 108 patients were enrolled, and the company expects to report topline data on the primary endpoint in the second half of 2027. This trial marks a critical step towards potential regulatory approval of bel-sar, which aims to be the first approved frontline, vision-preserving therapy for this condition. Aura has also received significant designations from both the FDA and EMA for this treatment.
Read more →AURAAura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 19, 2026
Aura Biosciences has announced inducement equity awards to its new CEO, Natalie Holles, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards include stock options, restricted stock units, and performance-based units, with specific vesting schedules. Aura aims to develop precision therapies for solid tumors, highlighting its commitment to innovation in oncology.
Read more →AURAAura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aura Biosciences has announced inducement equity awards for its new CEO, Natalie Holles, as part of her employment agreement. The awards include stock options, restricted stock units, and performance-based units, with specific vesting schedules. This move aligns with Nasdaq regulations and reflects the company's commitment to leadership in precision therapies for solid tumors.
Read more →AURAAura Biosciences to Participate in Upcoming May 2026 Investor Conferences
Aura Biosciences, a clinical-stage biotechnology company, announced its participation in upcoming investor conferences. The senior management team will engage in fireside chats, which will be available for live streaming and later archived. The company is dedicated to developing therapies for solid tumors, with its lead candidate in late-stage development.
Read more →AURAAura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences, Inc. announced that members of its senior management team will participate in key investor conferences in May 2026. The upcoming events include the H.C. Wainwright 4th Annual BioConnect Investor Conference and the TD Cowen 7th Annual Oncology Innovation Summit. The company focuses on precision therapies for solid tumors, with its lead candidate, bel-sar, in late-stage development for early choroidal melanoma. Live webcasts of the presentations will be available on the company's website, allowing for broader investor engagement.
Read more →AURAAura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive
Aura Biosciences reported its financial results for the first quarter of 2026, highlighting significant advancements in its clinical trials, particularly the Phase 3 CoMpass trial for early choroidal melanoma. The trial is nearing completion of patient enrollment and is expected to provide topline data in the second half of 2027. The company also strengthened its financial standing with a $299 million equity financing, which is expected to support operations into mid-2028. Natalie Holles has been appointed as the new CEO, replacing the founder, indicating a shift in leadership.
Read more →AURA▲ +6.6%on this news
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Aura Biosciences has successfully closed a public offering, raising approximately $299.4 million. The offering included the sale of over 46 million shares of common stock, with additional pre-funded warrants. This funding will support Aura's ongoing development of precision therapies for solid tumors, including its lead candidate for ocular oncology.
Read more →AURA▲ +19.1%on this newsshared move
Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion
Aura Biosciences has appointed Natalie Holles as the new CEO, succeeding founder Elisabet de los Pinos. The company is nearing enrollment completion for its Phase 3 CoMpass trial of belzupacap sarotalocan (bel-sar) for early choroidal melanoma, with expectations to finalize enrollment by mid-2026 and release topline data in late 2027. Holles brings extensive experience in rare disease commercialization and is poised to lead the company through this critical phase.
Read more →AURA▲ +19.1%on this newsshared move
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Aura Biosciences has announced a proposed public offering of its common stock and pre-funded warrants. The offering, which is subject to market conditions, aims to raise funds for the company's development of precision therapies for solid tumors. Aura has granted underwriters a 30-day option to purchase additional shares. The final terms will be disclosed in a prospectus supplement filed with the SEC.
Read more →AURA▲ +19.1%on this newsshared move
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants
Aura Biosciences has announced the pricing of a public offering totaling $260 million, which includes shares of common stock and pre-funded warrants. The proceeds will primarily support clinical programs for early choroidal melanoma and other initiatives. The offering is expected to close on May 5, 2026, pending customary conditions.
Read more →AURAAura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase
Aura Biosciences has reported its financial results for Q4 and the full year of 2025, highlighting significant progress in clinical trials, particularly the Phase 3 CoMpass trial for early choroidal melanoma. Enhanced enrollment anticipates completion by mid-2026, with topline data expected in the second half of 2027. The company has demonstrated stability for a new formulation aimed at non-ocular solid tumors, specifically in urologic oncology. However, financial performance shows a growing net loss, raising questions about future funding sustainability amidst ongoing trial costs.
Read more →AURAAura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference
Aura Biosciences, a clinical-stage biotechnology company, announced its participation in the 8th Annual Evercore Healthcare Conference. CEO Elisabet de los Pinos is scheduled to partake in a fireside chat on December 2, 2025. The discussion will be accessible via a live webcast and will be archived for 90 days. The company continues to focus on developing precision therapies for solid tumors, particularly in late-stage development for early choroidal melanoma.
Read more →AURAAura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights
Aura Biosciences reported its third quarter 2025 financial results, highlighting progress in its Phase 3 CoMpass trial for early choroidal melanoma and a Phase 1b/2 trial for NMIBC. The company anticipates completing enrollment for the CoMpass trial in 2026, with topline data expected in Q4 2027. Recent immune profiling data supports the potential of bel-sar as a frontline therapy for bladder cancer and other solid tumors.
Read more →AURAAura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Aura Biosciences, a clinical-stage biotechnology company, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. CEO Elisabet de los Pinos will present on September 10, 2025. The event aims to showcase the company's innovative therapies for solid tumors, particularly its lead candidate, bel-sar (AU-011). A live webcast will be available for interested parties.
Read more →AURAAura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights Continued Clinical Program Execution in the Phase 3 CoMpass Trial in Early Choroidal Melanoma and the Phase 1b/2 Trial in Non-Muscle
Aura Biosciences reported its financial results for Q2 2025, highlighting successful equity financing of $75 million, which will support operations into mid-2027. The company is actively enrolling patients in its global Phase 3 CoMpass trial for early choroidal melanoma and a Phase 1b/2 trial for non-muscle invasive bladder cancer. Despite the positive developments, Aura reported a net loss of $27 million, up from the previous year, reflecting increased research and development costs. The firm also filed a patent application for a new formulation of its lead candidate, bel-sar, designed to improve treatment administration in urologic oncology.
Read more →AURA▲ +14.9%on this news
May 2025 Innovating the future of cancer care to cure patients and preserve organ function Legal disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this caut
AURA is advancing multiple clinical programs aimed at treating ocular and urologic cancers through innovative drug conjugates. The company has reported positive data from Phase 2 trials, showing efficacy in targeting tumors and preserving organ function. Upcoming readouts for ongoing studies are expected in 2025, and the company believes it is well-funded to continue its operations into the first half of 2027. AURA emphasizes the significant unmet medical needs for effective localized treatments in its target markets, which enhances its market potential.
Read more →AURA▲ +18.9%on this news· ran to +37% by day 1shared move
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants
Aura Biosciences announced the pricing of a public offering of common stock and warrants, aiming to raise $75 million. The offering includes 11.7 million shares of common stock and pre-funded warrants. Proceeds will support clinical programs for various cancers. The offering is expected to close on May 16, 2025, pending customary conditions.
Read more →AURA▲ +5.7%on this news· ran to +21% by day 1shared move
Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Mont
Aura Biosciences announced its financial results for the first quarter of 2025, showcasing progress in its clinical pipeline. The company has enrolled its first patient in a multi-dose Phase 1b/2 trial of bel-sar for non-muscle-invasive bladder cancer, with initial data expected by the end of 2025. The firm reported a net loss of $27.5 million and an increase in research and development expenses as they advance their trials. Additionally, the appointment of Tony Gibney as Chief Financial and Business Officer is anticipated to enhance the leadership team's capabilities.
Read more →AURA▲ +5.7%on this news· ran to +21% by day 1shared move
Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants
Aura Biosciences, a biotechnology firm, has announced a public offering of common stock and accompanying warrants. The offering is subject to market conditions, and details regarding the size and terms have yet to be finalized. Aura aims to utilize the funds to support its ongoing development of precision therapies targeting solid tumors. The company's lead candidate, bel-sar (AU-011), is in late-stage development for choroidal melanoma and early-stage development for additional indications.
Read more →AURAAura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors
Aura Biosciences has appointed Teresa Bitetti, President of Takeda's Global Oncology Business Unit, to its Board of Directors effective March 31, 2025. CEO Elisabet de los Pinos expressed confidence in Bitetti's leadership and experience to advance the company's clinical pipeline in oncology. Bitetti's background includes significant roles at Bristol Myers Squibb and a focus on innovative therapies.
Read more →AURA▼ -6.7%on this news· ran to -21% by day 3
Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress
Aura Biosciences announced positive results from a Phase 1 trial of bel-sar in patients with non-muscle-invasive bladder cancer (NMIBC). The trial demonstrated clinical complete responses in several patients, particularly those with intermediate-risk disease. The treatment exhibited a favorable safety profile, with minimal adverse events reported. These findings suggest that bel-sar could represent a new front-line treatment option for NMIBC.
Read more →AURA▼ -6.7%on this news· ran to -21% by day 3shared move
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC) Presented at the 40 th Annual European Associ
Aura Biosciences has reported positive Phase 1 trial data for its lead compound, bel-sar, in treating non-muscle invasive bladder cancer (NMIBC), highlighting the drug's potential as a front-line treatment. The company is also advancing its clinical pipeline, with active enrollment in the Phase 3 CoMpass trial for early-stage choroidal melanoma, while exploring additional indications for bel-sar. Financially, Aura reported a net loss increase but maintains cash reserves expected to support operations into 2026. These results and advancements are presented against the backdrop of Aura's ongoing efforts to address significant unmet medical needs in oncology.
Read more →AURAAura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress
Aura Biosciences has announced that it will present additional Phase 1 trial data for its treatment bel-sar (AU-011) for non-muscle invasive bladder cancer at the 40th Annual European Association of Urology Congress in Madrid. The company will also participate in a research forum during the event and host a virtual oncology investor event featuring key opinion leaders. These events are expected to provide further insights into the safety and efficacy of bel-sar and inform future clinical trials for bladder cancer. Key presentations are scheduled for March 22 and 23, 2025.
Read more →AURAAura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Aura Biosciences, a clinical-stage biotechnology company, announced its participation in the 7th Annual Evercore ISI HealthCONx Conference on December 3, 2024. CEO Elisabet de los Pinos, PhD, will take part in a fireside chat during the event. This conference provides an opportunity for the company to showcase its efforts in developing precision therapies for solid tumors. Additionally, a live webcast of the discussion will be available on the company's website, allowing broader access to potential investors and media.
Read more →AURAAura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights Positive Phase 2 End of Study Data with Bel-sar in Early-Stage Choroidal Melanoma; Ongoing Phase 3 CoMpass Trial Recently Received Aut
Aura Biosciences has reported positive financial results for Q3 2024, highlighting significant clinical progress with their drug bel-sar in treating early-stage choroidal melanoma and non-muscle invasive bladder cancer. The company announced an 80% tumor control rate in Phase 2 trials and received authorization to commence a Phase 3 trial in Europe. They also maintain a strong cash reserve expected to sustain operations until the second half of 2026, allowing further development of bel-sar across various oncology indications.
Read more →AURAMultiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial Clinical Complete Responses Obser
Aura Biosciences has reported encouraging results from its ongoing Phase 1 clinical trial of bel-sar (AU-011) for non-muscle-invasive bladder cancer (NMIBC). Out of 13 participants, 4 of 5 patients with low-grade disease achieved a clinical complete response following a single low dose treatment. The trial demonstrated a favorable safety profile with minimal adverse effects observed. The data also suggests potential immune activation indicative of a wider treatment effect, leading to plans for expanding into a Phase 2 trial.
Read more →AURA▲ +7.9%on this news
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First- Line Treatment for Early-Stage Choroidal Melanoma Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation,
Aura Biosciences announced positive results from a Phase 2 study evaluating bel-sar as a first-line treatment for early-stage choroidal melanoma. The study demonstrated an 80% tumor control rate and 90% visual acuity preservation among participants, showing significant potential for this novel therapy. The findings, presented at The Retina Society Annual Meeting, highlight the favorable safety profile of bel-sar, with no serious adverse events reported. Aura is progressing towards a Phase 3 trial, aiming to further investigate bel-sar's efficacy and safety in larger patient populations.
Read more →AURA▼ -7%on this news
Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024
Aura Biosciences, a clinical-stage biotechnology firm, has announced a virtual investor event set for October 17, 2024, where early data from its ongoing Phase 1 trial on non-muscle invasive bladder cancer (NMIBC) will be presented. The event will include discussions from key opinion leaders about the current treatment landscape and the significant unmet medical needs in NMIBC. Additionally, the company is expanding its leadership team with Dr. Sabine Brookman-May, who brings over 20 years of experience in the field, particularly in bladder cancer development.
Read more →AURAAura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting
Aura Biosciences has announced the presentation of Phase 2 end of study data for bel-sar, a treatment for early-stage choroidal melanoma. This presentation will occur at The Retina Society Annual Meeting held in Lisbon from September 11-15, 2024. The data, presented by Dr. Ivana Kim of Mass Eye and Ear, aims to evaluate the safety and effectiveness of the suprachoroidal administration method. Additionally, a virtual investor event will facilitate further discussion on the findings.
Read more →AURAAura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights Company to Present Early Non-muscle Invasive Bladder Cancer (NMIBC) Data from Ongoing Phase 1 Trial at a Urologic Oncology Investor E
Aura Biosciences has announced its financial results for Q2 2024, reporting a cash position of $187.4 million which is expected to fund operations through the second half of 2026. The company is gearing up to present early data from its ongoing Phase 1 trial for non-muscle invasive bladder cancer at an upcoming urologic oncology investor event in October. Additionally, Phase 2 data for bel-sar in treating choroidal melanoma will be showcased at the Retina Society Annual Meeting in September. However, the company has reported an increased net loss compared to the previous year, raising concerns about its financial sustainability.
Read more →AURACorporate Presentation June 2024 Legal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements c
The corporate presentation from AURA focuses on forward-looking statements related to their research and development programs, including the initiation and timing of clinical trials. It emphasizes ongoing studies in areas of unmet medical need, particularly in ocular oncology, where the company believes it has significant market opportunities. Key upcoming clinical data readouts are expected within the next six to twelve months, and the company anticipates having sufficient cash to fund operations into the second half of 2026. However, the presentation also highlights inherent risks associated with the commercialization and regulatory approval of their product candidates.
Read more →AURAAura Biosciences to Participate in the Jefferies Global Healthcare Conference
Aura Biosciences, a clinical-stage biotechnology company, announced that its CEO, Elisabet de los Pinos, will present at the Jefferies Global Healthcare Conference on June 6, 2024. The company focuses on developing precision immunotherapies designed to treat solid tumors while preserving organ functions. Their lead candidate, bel-sar, is currently in late-stage clinical development targeting primary uveal melanoma and is also being evaluated for bladder cancer. The live presentation will be available via webcast on the company's website.
Read more →AURAAura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024
Aura Biosciences, a clinical-stage biotechnology company, announced it will host a virtual Key Opinion Leader (KOL) event on May 29, 2024. The event will feature discussions by leading experts in ocular oncology about the current treatment landscape and highlight Aura's late-stage therapy candidate, bel-sar, aimed at treating early-stage uveal melanoma. A live Q&A session will allow participants to engage with the KOLs and explore further insights into ocular cancer treatments. This event underscores Aura's commitment to pioneering new standards of care in this specialized field.
Read more →AURAAura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoing Phase 1 Trial in Bl
Aura Biosciences has reported its financial results for the first quarter of 2024, highlighting continued enrollment in its Phase 3 CoMpass trial for small choroidal melanoma. The company anticipates early data from its Phase 1 bladder cancer trial by mid-2024 and has a strong cash position that will support operations into the latter half of 2026. However, Aura recorded a net loss of $19.7 million for the quarter, which has increased compared to the previous year, alongside rising research and development expenses. The company remains focused on developing precision immunotherapies aimed at preserving organ function while treating solid tumors.
Read more →AURAAura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights Enrolling Patients in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions; Granted SPA A
Aura Biosciences reported its financial results for Q4 and the full year 2023, highlighting significant advancements in its clinical pipeline. The company is actively enrolling patients in its Phase 3 CoMpass trial for small choroidal melanoma and recently received FDA's SPA agreement for the trial's design. Despite a strong cash position of $226.2 million to support operations through 2026, the company faces increasing net losses and rising expenses associated with its ongoing research and development efforts. Positive preliminary data from Phase 2 trials further bolster the company's outlook in ocular oncology and bladder cancer indications.
Read more →AURALegal Disclosure This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified
Aura Biosciences provided a corporate presentation highlighting its advancements in oncology, specifically targeting choroidal melanoma and choroidal metastasis. The company is currently enrolling participants in a Phase 3 trial and has a strong financial position expected to sustain operations until the second half of 2026. However, the presentation includes numerous forward-looking statements that underline various risks and uncertainties related to the progress and outcomes of their research and development programs. Notably, the clinical candidates discussed are still in preclinical or clinical evaluation and have not received regulatory approval for marketing.
Read more →AURAAura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights Received FDA Agreement Under Special Protocol Assessment (SPA) for the CoMpass Phase 3 Clinical T
Aura Biosciences reported its third quarter 2023 financial results, highlighting key clinical developments, including FDA agreement for the CoMpass Phase 3 trial. Encouraging efficacy updates from the Phase 2 trial of bel-sar for early-stage choroidal melanoma were shared, showing a 90% visual acuity preservation rate. Additionally, promising Phase 1 trial results in bladder cancer were noted, with a clinical complete response observed in the first patient. The company raised $99 million in an underwritten public offering, positioning itself strongly for future clinical milestones.
Read more →AURA▼ -8.2%on this news· ran to -41% by day 3shared move
Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma Positive Clinical Efficacy Updates
Aura Biosciences has received FDA agreement under a Special Protocol Assessment for its Phase 3 CoMpass clinical trial evaluating belzupacap sarotalocan (Bel-sar) for early-stage Choroidal Melanoma. Positive data from Phase 2 trials showed 90% visual acuity preservation and 80% tumor control. The upcoming trial is set to include approximately 100 patients and aims for a biologics license application submission if successful. This trial marks a significant step in potential new therapies for ocular oncology.
Read more →AURA▼ -7.5%on this news
Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments J. Jill Hopkins, M.D., Appointed as Chief Medical Officer and President of Research & Development Mark Plavsic, Ph.D., Appointed as Chief Tec
Aura Biosciences has announced the appointments of J. Jill Hopkins, M.D., as Chief Medical Officer and Mark Plavsic, Ph.D., as Chief Technology Officer. These appointments come as Aura progresses into a critical phase in its development of virus-like drug conjugate therapies for oncology. The company aims to advance its lead candidate, bel-zupacap sarotalocan, into a global Phase 3 trial focused on early-stage choroidal melanoma. Cadmus Rich, M.D., will transition to a Senior Clinical Advisor role, remaining with the organization in an advisory capacity.
Read more →AURA▼ -6.6%on this news
Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights Strengthened Clinical and Regulatory Leadership Team with Key Appointments Start-up Activities f
Aura Biosciences reported its second quarter 2023 financial results, highlighting progress in clinical development and operational efforts. The company has strengthened its leadership team with key appointments and is actively working on its global Phase 3 trial, set to begin dosing patients in the second half of 2023. Financial results show an increase in research and development expenses, leading to a higher net loss compared to the previous year. Despite these challenges, Aura has sufficient cash reserves to fund operations into 2025, supporting its ongoing initiatives in oncology.
Read more →AURAAura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights U.S. Food and Drug Administration (FDA) Guidance in Type C Meeting Supports Global Phase 3 Trial
Aura Biosciences has reported its financial results for Q1 2023, highlighting significant clinical advancements. The company is preparing for a pivotal Phase 3 trial for its lead therapy, belzupacap sarotalocan (bel-sar), targeting early-stage choroidal melanoma, following encouraging feedback from the FDA. Additionally, enrollment has been completed in a Phase 2 trial, and they are working on a Phase 1 trial for non-muscle invasive bladder cancer. Despite a rising net loss and increasing research expenses, Aura's strong cash position supports its ongoing development plans.
Read more →AURAAura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Belzupac
Aura Biosciences reported its fourth quarter and full year 2022 financial results, highlighting significant clinical advancements for belzupacap sarotalocan (bel-sar). The FDA granted Fast Track Designation for bel-sar in the treatment of choroidal metastasis, marking its second ocular oncology indication to receive this status. Positive interim Phase 2 safety and efficacy data support the upcoming Phase 3 trial set to begin in 1H 2023. However, Aura also reported increased research and development expenses and a substantial net loss for the year.
Read more →AURA▼ -7.2%on this news
Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administra
Aura Biosciences has announced positive interim Phase 2 safety and efficacy data for its experimental therapy belzupacap sarotalocan (bel-sar) as a first-line treatment for early-stage choroidal melanoma. The data, presented at the Macula Society annual meeting, showed an impressive tumor control rate and a favorable safety profile. Only one patient experienced a loss of visual acuity, and the results indicate a potential paradigm shift in treating this form of eye cancer, with the global Phase 3 trial set to begin enrollment soon. Aura's lead candidate is designed to selectively target cancer cells while preserving vision.
Read more →AURAAura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights Announced the Global Phase 3 Trial Design with Suprachoroidal Route of Administration of Belzupac
Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights Announced the Global Phase 3 Trial Design with Suprachoroidal Route of Administration of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma First Pat
Read more →AURA▼ -19.5%on this news
Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 20
Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022 Aura to Host Virtual Investor Day at 11:30 a.m. Eastern
Read more →AURA▲ +19.2%on this newsshared move
Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer BOSTON, MA
Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer MA September 28, 2022 Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a nove
Read more →AURA▼ -8.6%on this news
Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights On Track to Dose the First Patient in the Phase 1 Study Evaluating Belzupacap Sarotalocan (AU&#x
Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights On Track to Dose the First Patient in the Phase 1 Study Evaluating Belzupacap Sarotalocan (AU 011) for the Treatment of Non-Muscle Invasive Bladder Cancer
Read more →AURA▲ +12.7%on this news
Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer CAMBRIDGE, Mass. (BUSINESS WIRE) Aura Biosciences, Inc. (NASDAQ: AURA), a c
Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer Mass. (BUSINESS WIRE) Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of viru
Read more →AURAAura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-
Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma In this Retrospective Matched Case
Read more →AURAAura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting CAMBRIDGE, MA
Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting CAMBRIDGE, MA May 26, 2022 Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel cl
Read more →AURAAura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights On Track to Meet Multiple Clinical Milestones for AU-011 in 2H 2022: Initiate Pivotal Trial in Ch
Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights On Track to Meet Multiple Clinical Milestones for AU-011 in 2H 2022: Initiate Pivotal Trial in Choroidal Melanoma, Initiate Phase 1 Trial in Non-Muscle Inva
Read more →AURAAura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights On Track to Initiate Pivotal Trial in Choroidal Melanoma and Phase 1 Trial in Non-
Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights On Track to Initiate Pivotal Trial in Choroidal Melanoma and Phase 1 Trial in Non-Muscle Invasive Bladder Cancer with AU-011 in 2H 2022 Orph
Read more →AURA▲ +11.4%on this news· ran to +26% by day 1
Aura Biosciences Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights Presented Final Data from Phase 1b/2 Trial of AU-011 in Choroidal Melanoma at the American Academ
Aura Biosciences Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights Presented Final Data from Phase 1b/2 Trial of AU-011 in Choroidal Melanoma at the American Academy of Ophthalmology's Annual Meeting Completed Initial Publ
Read more →Competitive Position
How AURA ranks across every disease it competes inCompetitive Position is a premium feature
See how AURA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial